Literature DB >> 20182055

No association between neuregulin 1 and psychotic symptoms in Alzheimer's disease patients.

Fiona Middle1, Antonia L Pritchard, Herlina Handoko, Sayeed Haque, Roger Holder, Peter Bentham, Corinne L Lendon.   

Abstract

Alzheimer's disease (AD) patients commonly suffer from behavioral and psychological symptoms of dementia (BPSD). Variants within the neuregulin-1 (NRG1) gene have been investigated both in early onset psychiatric disorders, such as schizophrenia and recently in AD patients with psychosis. In this study, we analyzed NRG1 variants in AD patients with and without psychosis. Our large cohort of 399 probable AD patients had longitudinal information on the BPSD, which was used to dichotomize patients into whether they had ever suffered from psychotic symptoms within the study period. The NRG1 single nucleotide polymorphisms rs3924999, rs35753505 (SNP8NRG221533) and the microsatellites 478B14-848 and 420M9-1395 were investigated for association with psychosis using genotype, allele, and haplotype analyses. No associations were found between any of these variants or haplotypic combinations with delusions, hallucinations, psychosis, or elation/mania in our cohort. Positive associations with polymorphisms and haplotype combinations of NRG1 have been reported in psychiatric disorders. One previous study found an association with psychosis in AD, with a SNP outside the haplotype block first reported for association with schizophrenia. We found no association with any of these variants in our cohort. Further investigations of this region on chromosome 8 are clearly required, with replication in different large longitudinal cohorts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20182055     DOI: 10.3233/JAD-2010-1405

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  No association between NRG1 and ErbB4 genes and psychopathological symptoms of schizophrenia.

Authors:  Sarah Tosato; Martina Zanoni; Chiara Bonetto; Federica Tozzi; Clyde Francks; Elisa Ira; Simona Tomassi; Mariaelena Bertani; Dan Rujescu; Ina Giegling; David St Clair; Michele Tansella; Mirella Ruggeri; Pierandrea Muglia
Journal:  Neuromolecular Med       Date:  2014-08-21       Impact factor: 3.843

Review 2.  Neuregulin-ERBB signaling in the nervous system and neuropsychiatric diseases.

Authors:  Lin Mei; Klaus-Armin Nave
Journal:  Neuron       Date:  2014-07-02       Impact factor: 17.173

3.  Unveiling clusters of RNA transcript pairs associated with markers of Alzheimer's disease progression.

Authors:  Ahmed Shamsul Arefin; Luke Mathieson; Daniel Johnstone; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

Review 4.  Cerebral correlates of psychotic syndromes in neurodegenerative diseases.

Authors:  Kurt A Jellinger
Journal:  J Cell Mol Med       Date:  2012-05       Impact factor: 5.310

5.  Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model.

Authors:  Jiqing Xu; Fred de Winter; Catherine Farrokhi; Edward Rockenstein; Michael Mante; Anthony Adame; Jonathan Cook; Xin Jin; Eliezer Masliah; Kuo-Fen Lee
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

Review 6.  Clinical Aspects of Neurobehavioral Symptoms of Dementia.

Authors:  YoungSoon Yang; Nagaendran Kandiah; SangYun Kim; Yong Tae Kwak
Journal:  Dement Neurocogn Disord       Date:  2020-06

7.  The reemergence of long-term potentiation in aged Alzheimer's disease mouse model.

Authors:  Seonghoo Huh; Soo-Ji Baek; Kyung-Hwa Lee; Daniel J Whitcomb; Jihoon Jo; Seong-Min Choi; Dong Hyun Kim; Man-Seok Park; Kun Ho Lee; Byeong C Kim
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.